Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

Other equities research analysts also recently issued reports about the stock. Credit Suisse Group set a $201.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Citigroup Inc. reissued a “neutral” rating and set a $150.00 price target on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 19th. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Laidlaw reissued a “hold” rating and set a $119.00 price target (up from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC reissued a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research note on Sunday, July 30th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $174.93.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 61.59 on Friday. The company’s market capitalization is $1.55 billion. The company’s 50-day moving average is $106.75 and its 200-day moving average is $115.74. Intercept Pharmaceuticals has a one year low of $60.97 and a one year high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.14) earnings per share. Equities analysts predict that Intercept Pharmaceuticals will post ($13.91) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Stock Rating Lowered by ValuEngine” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/24/intercept-pharmaceuticals-inc-icpt-stock-rating-lowered-by-valuengine.html.

In other news, Director Daniel G. Welch sold 217 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total value of $27,506.92. Following the completion of the transaction, the director now owns 3,710 shares in the company, valued at $470,279.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO David Shapiro sold 1,250 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $117.43, for a total transaction of $146,787.50. Following the completion of the transaction, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. Insiders sold 48,013 shares of company stock valued at $6,198,747 in the last quarter. Corporate insiders own 9.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of Intercept Pharmaceuticals by 0.7% in the second quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock valued at $454,094,000 after buying an additional 25,958 shares during the period. Carmignac Gestion boosted its holdings in Intercept Pharmaceuticals by 0.4% during the second quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after purchasing an additional 7,400 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after purchasing an additional 57,149 shares during the last quarter. State Street Corp boosted its holdings in Intercept Pharmaceuticals by 7.3% during the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock worth $91,110,000 after purchasing an additional 54,523 shares during the last quarter. Finally, First Trust Advisors LP boosted its holdings in Intercept Pharmaceuticals by 17.0% during the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock worth $34,797,000 after purchasing an additional 41,856 shares during the last quarter. Institutional investors own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.